Daxxify (Daxibotulinumtoxina-Lanm) Patent Expiration, LOE Window & CMS Spending

Daxxify (Daxibotulinumtoxina-Lanm) by Revance Therapeutics: Biologic BLA (Purple Book Regime), 0 AB generics, $12K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRevance Therapeutics
FDA Application & PathwayB761127 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$12K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$12K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel